Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2014 Press Release: Docetaxel or Pemetrexed in Addition to Cisplatin Achieve Comparable Outcomes in Non-Squamous Lung Cancer

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.
27 Sep 2014
Lung and other thoracic tumours;  Anticancer agents & Biologic therapy

Lugano/Madrid, 27 September 2014 -- At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea.

“We wanted to conduct this study because pemetrexed plus platinum chemotherapy is the most commonly used regimen for treating patients with non-squamous NSCLC whose cancer does not have mutations that can be targeted by specific inhibitors,” Kim explained. “However, docetaxel plus platinum is another effective regimen in the first line treatment of lung cancer and there has been no direct comparison of pemetrexed plus cisplatin versus docetaxel plus cisplatin.”

In the study, researchers randomly assigned patients with chemotherapy-naive cancer to 3-weekly cisplatin 70 mg/m2 in addition to either docetaxel 60 mg/m2  or pemetrexed 500mg/m2  for up to 4 cycles. They recorded a median progression-free survival of 4.7 months in those who received the pemetrexed combination, and 4.6 months among those who received docetaxel.

However, the rate of serious adverse events was higher in the docetaxel group, they found, with 24 serious adverse events recorded among pemetrexed patients, and 42 in the docetaxel arm.

Kim notes that recruitment into the study was halted early when pemetrexed maintenance treatment was approved in Korea and its use became widespread. “As we stopped recruitment prematurely, we could not prove non-inferiority between the arms. However, the pemetrexed plus cisplatin arm was less toxic than the docetaxel plus cisplatin arm, while there was no significant difference in progression-free survival and response rate,” Kim said.

The researchers are continuing to follow patients in the trial to study whether there is any difference in overall survival between the arms.
Commenting on the study, Dr Solange Peters from the University Hospital of Lausanne, Switzerland, noted: ”The various available platinum-based regimen demonstrate quite similar activity in NSCLC.”

"While a dedicated larger trial published by Scagliotti in 2008 was able to show some superiority of platinum in combination with pemetrexed in non-squamous NSCLC, this trial also confirms its better tolerability, reinforcing most current international NSCLC treatment guidelines,” Peters said.

-END-

Notes to Editors

LBA41_PR: A randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin in first line non-squamous Non-Small Cell Lung cancer (NSq-NSCLC)

Disclaimer

Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view.

Session info

LBA41_PR        Saturday, September 27, 2014 – 16:00 PM – 17:45 PM  - Madrid

About the European Society for Medical Oncology

The European Society for Medical Oncology (ESMO) is the leading European professional organisation committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. ESMO’s mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice. The ESMO international community counts more than 9,000 oncology professionals sharing best practices and the latest know-how in cancer treatment and care. ESMO’s scientific journal, Annals of Oncology, ranks among the top 10 clinical oncology journals worldwide. To find out more about ESMO, please visit: www.esmo.org

Last update: 27 Sep 2014

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings